Baidu
map

JAMA Psychiatry:英国肿瘤患者自杀风险研究

2019-12-27 MedSci MedSci原创

尽管绝对数字很低,但癌症患者自杀的风险增加是一个令人担忧的问题,在诊断后的前6个月风险增加表明肿瘤患者的心理支持存在较大空白

肿瘤诊断对患者造成很大的心理困扰,近日研究人员量化了英国癌症患者的自杀风险。

研究人员使用英国国家癌症登记和分析服务中心数据,包含472099名癌症患者(2200万人-年风险)的死亡数据,不包括非黑色素瘤皮肤癌。研究的主要终点为自杀死亡,计算标准化死亡率(SMRs)和绝对额外风险(AERs)。

在4722099例癌症患者中,男性占50.3%,女性占49.7%。共有3509392名患者(74.3%)在确诊时年龄在60岁或60岁以上。共有2491名癌症患者(1719名男性和772名女性)死于自杀,占随访期间所有死亡人数的0.08%。自杀的总SMR为1.20,每10000人-年的AER为0.19。亚组分析显示,间皮瘤患者的风险最高,为4.51倍,相当于每10000人-年额外死亡4.20人,其次是胰腺癌(3.89倍)、食管癌(2.65倍)、肺癌(2.57倍)和癌(2.20倍)。自杀风险在癌症诊断后的前6个月最高(SMR:2.74)。

尽管绝对数字很低,但癌症患者自杀的风险增加是一个令人担忧的问题,在诊断后的前6个月风险增加表明肿瘤患者的心理支持存在较大空白。

原始出处:

Katherine E. Henson et al. Risk of Suicide After Cancer Diagnosis in England. JAMA Psychiatry. January, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1776640, encodeId=9c6d1e76640ca, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Thu Aug 20 18:21:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055691, encodeId=423f205569108, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792159, encodeId=56651e9215911, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Feb 23 20:21:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424305, encodeId=8d3614243056c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 29 09:21:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035845, encodeId=85831035845b6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Dec 27 21:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1776640, encodeId=9c6d1e76640ca, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Thu Aug 20 18:21:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055691, encodeId=423f205569108, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792159, encodeId=56651e9215911, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Feb 23 20:21:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424305, encodeId=8d3614243056c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 29 09:21:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035845, encodeId=85831035845b6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Dec 27 21:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1776640, encodeId=9c6d1e76640ca, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Thu Aug 20 18:21:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055691, encodeId=423f205569108, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792159, encodeId=56651e9215911, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Feb 23 20:21:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424305, encodeId=8d3614243056c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 29 09:21:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035845, encodeId=85831035845b6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Dec 27 21:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1776640, encodeId=9c6d1e76640ca, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Thu Aug 20 18:21:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055691, encodeId=423f205569108, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792159, encodeId=56651e9215911, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Feb 23 20:21:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424305, encodeId=8d3614243056c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 29 09:21:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035845, encodeId=85831035845b6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Dec 27 21:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1776640, encodeId=9c6d1e76640ca, content=<a href='/topic/show?id=457f8622190' target=_blank style='color:#2F92EE;'>#自杀风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86221, encryptionId=457f8622190, topicName=自杀风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65df38986519, createdName=Eleven24, createdTime=Thu Aug 20 18:21:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055691, encodeId=423f205569108, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792159, encodeId=56651e9215911, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Feb 23 20:21:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424305, encodeId=8d3614243056c, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Dec 29 09:21:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035845, encodeId=85831035845b6, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Dec 27 21:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=)]
    2019-12-27 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

女性肿瘤患者依从性管理的现状及思考

在当前的强化内分泌治疗策略和延长策略下,安全性管理,提高依从性是关键。辅助内分泌治疗的副作用是决定依从性的关键因素,并直接影响预后。阿那曲唑辅助治疗的依从性最高,中断内分泌治疗后的重启治疗DFS显着获益。雌激素水平抑制越强并不会增加整体疗效,相反与绝经后疾病风险增加相关。乳腺癌患者脂代谢、心脑血管安全以及骨安全的管理进一步决定了内分泌治疗的依从性。

Gut:浙江大学医学院徐骁教授团队Gut发表肝癌干性研究新成果

近日,国际著名消化杂志Gut在线发表了浙江大学医学院徐骁教授团队的题为USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation的研究论文。

肿瘤组织中某些细胞亚群的 · 2019-12-07

-->

新型抗肿瘤药物临床应用指导原则(2019年版)

第一部分  新型抗肿瘤药物临床应用指导原则   为规范新型抗肿瘤药物临床应用,提高肿瘤合理用药水平,保障医疗质量和医疗安全,维护肿瘤患者健康权益,特制定新型抗肿瘤药物临床应用指导原则。本指导原则涉及的新型抗肿瘤药物是指小分子靶向药物和大分子单克隆抗体类药物。   抗肿瘤药物临床应用的基本原则 抗肿瘤药物的应用涉及临床多个学科,合理应用抗肿瘤药物是

年终盘点:2019年肿瘤领域重磅级亮点研究成果丨梅斯医述评

2019年科学家们在肿瘤学研究领域发表了很多重磅级的研究,本文中小M就对2019年该领域发表的亮点研究进行整理,分享给大家!

2019年肿瘤领域研究进展盘点丨梅斯医述评

小M为您精选肿瘤领域年度研究热点。

Nature Cancer:PAK4抑制可促进PD-1免疫阻断疗法

免疫检查点阻断疗法已成为当今最热门的免疫疗法之一,该疗法显著改变了目前癌症治疗的格局,而PD-1(programmed cell death protein 1)免疫阻断疗法正是其中最典型的代表。

Baidu
map
Baidu
map
Baidu
map
Baidu
map